Quarterly ResultJun 3, 2026, 07:01 AM
Avalyn Pharma Upsizes IPO to $345M; Funds Operations into 2029
AI Summary
Avalyn Pharma Inc. announced its first quarter 2026 financial results and recent business highlights, including the completion of an upsized initial public offering (IPO) that raised approximately $345.0 million in gross proceeds. This capital, combined with existing cash, is projected to fund operations into 2029. The company also provided updates on its pipeline, with the AP01 MIST Phase 2b trial on track for mid-2026 enrollment completion and the AP02 AURA Phase 2 trial underway, both anticipating topline data by the end of 2027. Long-term open-label extension data for AP01 supported a favorable tolerability profile.
Key Highlights
- Avalyn Pharma completed an upsized IPO, raising gross proceeds of approximately $345.0 million.
- Cash, cash equivalents, and marketable securities were $123.1 million as of March 31, 2026.
- Including IPO proceeds, cash is projected to fund operations into 2029.
- Research & Development expenses increased to $22.9 million in Q1 2026 from $15.3 million in Q1 2025.
- General & Administrative expenses rose to $5.0 million in Q1 2026 from $3.4 million in Q1 2025.
- Net loss for Q1 2026 was $26.9 million, compared to $17.5 million in Q1 2025.
- MIST Phase 2b trial of AP01 in PPF is on track to complete enrollment mid-2026, with topline data in H2 2027.
- AURA Phase 2 trial of AP02 in IPF is underway, with topline data anticipated by end of 2027.
- AP03 Phase 1 trial is on track to initiate by the end of 2026.
Price Impact
More from AVLN